Translate

Wednesday, September 23, 2020

thumbnail

BLCM Bellicum Pharmaceuticals, Inc. gains 16% Sep 23, 2020

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.http://www.priceseries.com/trade/BLCM-Bellicum-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2020091020200923.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive